000788，董事长被刑拘！

Core Viewpoint - The chairman and president of Peking University Medicine, Xu Xiren, has been criminally detained and is temporarily unable to perform his duties, but the company's control remains unchanged and operations are normal [2][4]. Group 1: Company Leadership Changes - Xu Xiren has been detained and is cooperating with investigations, leading to a temporary delegation of his responsibilities to other executives [2][4]. - The company has arranged for the board to operate normally, and financial and operational management remains stable [4]. - Xu Xiren remains the actual controller of Peking University Medicine despite his detention [4][6]. Group 2: Background of Xu Xiren - Xu Xiren, born in April 1979, has a master's degree and has held various positions, including at Standard Chartered Bank [6]. - He acquired control of Peking University Medicine through a transaction involving the purchase of 100% of Southwest Synthetic Pharmaceutical Group for a nominal price, assuming significant debt [7]. - He has held the positions of actual controller, chairman, and president of the company since his appointment in July 2025 [7][8]. Group 3: Company Financial Performance - In the first half of 2025, Peking University Medicine reported revenues of 957 million yuan, a year-on-year decrease of 5.04%, while net profit attributable to shareholders was 100 million yuan, an increase of 15.51% [8]. - The termination of a long-term service contract with Peking University International Hospital in April 2025 is expected to negatively impact sales revenue and net profit in the second half of 2025 [8]. Group 4: Market Performance - As of October 29, the stock price of Peking University Medicine closed at 6.17 yuan per share, with a total market capitalization of 3.677 billion yuan [9].